Enveda, the biotechnology company learning from life鈥檚 chemistry to create better medicines faster, has closed a substantial Series e funding round, securing $311.0M. The investment, led by Catalio Capital Management, signals strong backing for Enveda's unique AI-powered platform.
This technology identifies and characterizes a vast array of previously unexplored molecules from living organisms, creating a comprehensive "library of life" that translates nature's evolved solutions into new treatments for today's pressing medical needs.

















